166 related articles for article (PubMed ID: 31274625)
1. Thyroid Cancer Bone Metastasis: Survival and Genomic Characteristics of a Large Tertiary Care Cohort.
Kondraciuk JD; Rice SL; Zhou X; Gharzeddine K; Knezevic A; Spratt DE; Sabra M; Larson SM; Grewal RK; Osborne JR
Clin Nucl Med; 2019 Aug; 44(8):e465-e471. PubMed ID: 31274625
[TBL] [Abstract][Full Text] [Related]
2. Thyroid Cancer Brain Metastasis: Survival and Genomic Characteristics of a Large Tertiary Care Cohort.
Osborne JR; Kondraciuk JD; Rice SL; Zhou X; Knezevic A; Spratt DE; Sabra M; Larson SM; Grewal RK
Clin Nucl Med; 2019 Jul; 44(7):544-549. PubMed ID: 31107749
[TBL] [Abstract][Full Text] [Related]
3. Improved Survival After Multimodal Approach with
Wu D; Gomes Lima CJ; Moreau SL; Kulkarni K; Zeymo A; Burman KD; Wartofsky L; Van Nostrand D
Thyroid; 2019 Jul; 29(7):971-978. PubMed ID: 31017051
[No Abstract] [Full Text] [Related]
4. Risk Stratification Using a Novel Genetic Classifier Including
Jung CK; Jung SH; Jeon S; Jeong YM; Kim Y; Lee S; Bae JS; Chung YJ
Thyroid; 2020 Nov; 30(11):1589-1600. PubMed ID: 32326836
[No Abstract] [Full Text] [Related]
5. Highly Concordant Key Genetic Alterations in Primary Tumors and Matched Distant Metastases in Differentiated Thyroid Cancer.
Sohn SY; Park WY; Shin HT; Bae JS; Ki CS; Oh YL; Kim SW; Chung JH
Thyroid; 2016 May; 26(5):672-82. PubMed ID: 26971368
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcome after bone metastasis (BM) surgery in patients with differentiated thyroid carcinoma (DTC): a retrospective study of 40 cases.
Nakayama R; Horiuchi K; Susa M; Watanabe I; Watanabe K; Tsuji T; Matsumoto M; Toyama Y; Morioka H
Jpn J Clin Oncol; 2014 Oct; 44(10):918-25. PubMed ID: 25104791
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors and the therapeutic strategy for patients with bone metastasis from differentiated thyroid carcinoma.
Orita Y; Sugitani I; Matsuura M; Ushijima M; Tsukahara K; Fujimoto Y; Kawabata K
Surgery; 2010 Mar; 147(3):424-31. PubMed ID: 20176243
[TBL] [Abstract][Full Text] [Related]
8. Clinical management and outcomes in patients with hyperfunctioning distant metastases from differentiated thyroid cancer after total thyroidectomy and radioactive iodine therapy.
Qiu ZL; Shen CT; Luo QY
Thyroid; 2015 Feb; 25(2):229-37. PubMed ID: 25331724
[TBL] [Abstract][Full Text] [Related]
9. Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases.
Xu B; Fuchs T; Dogan S; Landa I; Katabi N; Fagin JA; Tuttle RM; Sherman E; Gill AJ; Ghossein R
Thyroid; 2020 Oct; 30(10):1505-1517. PubMed ID: 32284020
[No Abstract] [Full Text] [Related]
10. Differentiated thyroid carcinoma presenting with distant metastasis at initial diagnosis clinical outcomes and prognostic factors.
Lee J; Soh EY
Ann Surg; 2010 Jan; 251(1):114-9. PubMed ID: 19779325
[TBL] [Abstract][Full Text] [Related]
11. LONG-TERM OUTCOMES AND PROGNOSTIC FACTORS IN PATIENTS WITH DIFFERENTIATED THYROID CARCINOMA AND BONE METASTASES.
Slook O; Levy S; Slutzky-Shraga I; Tsvetov G; Robenshtok E; Shimon I; Benbassat C; Hirsch D
Endocr Pract; 2019 May; 25(5):427-437. PubMed ID: 30657361
[No Abstract] [Full Text] [Related]
12. Effect of BRAF
Mu ZZ; Zhang YQ; Sun D; Lu T; Lin YS
Endocr Pract; 2022 Mar; 28(3):265-270. PubMed ID: 34890787
[TBL] [Abstract][Full Text] [Related]
13. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.
Brose MS; Cabanillas ME; Cohen EE; Wirth LJ; Riehl T; Yue H; Sherman SI; Sherman EJ
Lancet Oncol; 2016 Sep; 17(9):1272-82. PubMed ID: 27460442
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib in Metastatic Papillary Thyroid Carcinoma with
Caterino M; Pirozzi M; Facchini S; Zotta A; Sica A; Lo Giudice G; Rauso R; Varriale E; Ciardiello F; Fasano M
Medicina (Kaunas); 2022 May; 58(5):. PubMed ID: 35630083
[TBL] [Abstract][Full Text] [Related]
15. Prognosis After Brain Metastasis from Differentiated Thyroid Carcinoma.
Saito F; Uruno T; Shibuya H; Kitagawa W; Nagahama M; Sugino K; Ito K
World J Surg; 2016 Mar; 40(3):574-81. PubMed ID: 26762631
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
Qiu ZL; Xue YL; Song HJ; Luo QY
Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the prognostic factors associated with cancer-specific survival of differentiated thyroid carcinoma presenting with distant metastasis.
Lang BH; Wong KP; Cheung CY; Wan KY; Lo CY
Ann Surg Oncol; 2013 Apr; 20(4):1329-35. PubMed ID: 23104708
[TBL] [Abstract][Full Text] [Related]
18. Differentiated thyroid carcinoma with distant metastases at presentation: prognostic factors and outcome.
Haq M; Harmer C
Clin Endocrinol (Oxf); 2005 Jul; 63(1):87-93. PubMed ID: 15963067
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes and prognostic factors in patients with no less than three distant organ system metastases from differentiated thyroid carcinoma.
Zhang XY; Sun JW; Qiu ZL; Wang Y; Chen XY; Zhao JH; Luo QY
Endocrine; 2019 Nov; 66(2):254-265. PubMed ID: 31317522
[TBL] [Abstract][Full Text] [Related]
20. Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients.
Song YS; Lim JA; Choi H; Won JK; Moon JH; Cho SW; Lee KE; Park YJ; Yi KH; Park DJ; Seo JS
Cancer; 2016 May; 122(9):1370-9. PubMed ID: 26969876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
